Your browser doesn't support javascript.
loading
Prevalence and predictors of polypharmacy and comorbidities among patients with chronic obstructive pulmonary disease: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia.
Alwafi, Hassan; Naser, Abdallah Y; Ashoor, Deema S; Alsharif, Alaa; Aldhahir, Abdulelah M; Alghamdi, Saeed M; Alqarni, Abdallah A; Alsaleh, Nada; Samkari, Jamil A; Alsanosi, Safaa M; Alqahtani, Jaber S; Dairi, Mohammad Saleh; Hafiz, Waleed; Tashkandi, Mohammed; Ashoor, Abdullah; Badr, Omaima Ibrahim.
Afiliación
  • Alwafi H; Department of Pharmacology and Toxicology, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Naser AY; Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman, Jordan. abdallah.naser@iu.edu.jo.
  • Ashoor DS; Faculty of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia.
  • Alsharif A; Department of Pharmacy Practice, College of Pharmacy, Princess Noura Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Aldhahir AM; Respiratory Therapy Department, Faculty of Applied Medical Sciences, Jazan, Saudi Arabia.
  • Alghamdi SM; Clinical Technology Department, Respiratory Care Program, Faculty of Applied Sciences, Umm Al-Qura University, Mecca, Saudi Arabia.
  • Alqarni AA; Department of Respiratory Therapy, Faculty of Medical Rehabilitation Sciences, King Abdulaziz University, Jeddah, 22230, Saudi Arabia.
  • Alsaleh N; Respiratory Therapy Unity, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
  • Samkari JA; Department of Pharmacy Practice, College of Pharmacy, Princess Noura Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Alsanosi SM; Family and Community Medicine Department, Faculty of Medicine in Rabigh, King Abdulaziz University, Rabigh, Saudi Arabia.
  • Alqahtani JS; Department of Pharmacology and Toxicology, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Dairi MS; Department of Respiratory Care, Prince Sultan Military College of Health Sciences, Dammam, 34313, Saudi Arabia.
  • Hafiz W; Department of Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Tashkandi M; Department of Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Ashoor A; Ministry of Health, Mecca, Saudi Arabia.
  • Badr OI; Faculty of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia.
BMC Pulm Med ; 24(1): 453, 2024 Sep 14.
Article en En | MEDLINE | ID: mdl-39272014
ABSTRACT

OBJECTIVE:

This study aimed to determine the prevalence of polypharmacy, comorbidities and to investigate factors associated with polypharmacy among adult patients with Chronic Obstructive Pulmonary Disease (COPD).

METHODS:

This was a retrospective single-centre cross-sectional study. Patients with a confirmed diagnosis of COPD according to the GOLD guidelines between 28 February 2020 and 1 March 2023 were included in this study. Patients were excluded if a pre-emptive diagnosis of COPD was made clinically without spirometry evidence of fixed airflow limitation. Population characteristics were presented as frequency for categorical variable. Logistic regression analysis was used to identify predictors of polypharmacy.

RESULTS:

The study sample included a total of 705 patients with COPD. Most of the study sample were males (60%). The mean age of the study population was 65 years old. The majority of the study population had comorbid diseases (68%), hypertension and diabetes were the most common co-existent diseases. Around 55% of the study sample had polypharmacy. Females were significantly less likely to be on polypharmacy compared to males (OR = 0.68, 95% CI = [0.50-0.92], P-value = 0.012)). On the other hand, older patients aged 65.4 or more (OR = 2.31, 95% CI = [1.71-3.14], P-value ≤ 0.001), those with high BMI (≥ 29.2) (OR = 1.42, 95% CI = [1.05-1.92], P-value = 0.024), current smokers (OR = 1.9, 95% CI = [1.39-2.62], P-value ≤ 0.001), those who are receiving home care (OR = 5.29, 95% CI = [2.46-11.37], P-value ≤ 0.001), those who have comorbidities (OR = 19.74, 95% CI = [12.70-30.68], P-value ≤ 0.001) were significantly more likely to be on polypharmacy (p ≤ 0.05).

CONCLUSIONS:

Polypharmacy is common among patients with COPD. Patients with high BMI, previous ICU hospitalization and older age are more likely to have polypharmacy. Future analytical studies are warranted to investigate outcomes in patients with COPD and polypharmacy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Comorbilidad / Polifarmacia / Enfermedad Pulmonar Obstructiva Crónica / Centros de Atención Terciaria Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: BMC Pulm Med Año: 2024 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Comorbilidad / Polifarmacia / Enfermedad Pulmonar Obstructiva Crónica / Centros de Atención Terciaria Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: BMC Pulm Med Año: 2024 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Reino Unido